SCHEMBL18532439

SCHEMBL18532439

COc1cccc(/C(N)=C/C=C(/O)C=O)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PARP1 P09874 1/20 0.55
▸ PRSS1 P07477 1/20 0.51
▸ PRSS2 P07478 1/20 0.51
▸ PRSS3 P35030 1/20 0.51
▸ CES2 O00748 1/20 0.50
▸ CES1 P23141 1/20 0.50
▸ NPC1 O15118 4/20 0.47
▸ RAB9A P51151 3/20 0.47
▸ MAOB P27338 1/20 0.46
▸ ABCG2 Q9UNQ0 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ CHRM2 P08172 1/20 0.44
▸ CHRM1 P11229 1/20 0.44
▸ CHRM3 P20309 1/20 0.44
▸ STS P08842 1/20 0.43
▸ MEN1 O00255 3/20 0.43
▸ KMT2A Q03164 3/20 0.43
▸ KCNK3 O14649 1/20 0.43
▸ KCNK9 Q9NPC2 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19145357 0.77 ALDH1A1 (0.45) PARP1PRSS1PRSS2PRSS3CES2
SCHEMBL17020590 0.77 PARP1 (0.56) PARP1PRSS1PRSS2PRSS3CES2
SCHEMBL2327652 0.73 CES2 (0.67) PARP1PRSS1PRSS2PRSS3CES2
SCHEMBL283787 0.72 PARP1 (1.00) PARP1PRSS1PRSS2PRSS3CES2
SCHEMBL29503138 0.72 PARP1 (1.00) PARP1PRSS1PRSS2PRSS3CES2
SCHEMBL11120856 0.72 PARP1 (0.57) PARP1PRSS1PRSS2PRSS3CES2
SCHEMBL11120852 0.72 PARP1 (0.57) PARP1PRSS1PRSS2PRSS3CES2
SCHEMBL11161428 0.72 PARP1 (0.57) PARP1PRSS1PRSS2PRSS3CES2
SCHEMBL11117845 0.72 PDE4A (0.65) PARP1PRSS1PRSS2PRSS3CES2
SCHEMBL11188244 0.72 PARP1 (0.57) PARP1PRSS1PRSS2PRSS3CES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170204083-A1 THERAPEUTIC HYDROXYPYRIDINONES, HYDROXYPYRIMIDINONES AND HYDROXYPYRIDAZINONES RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2017-07-20 — — US disclosed
US-9573938-B2 Therapeutic hydroxypyridinones, hydroxypyrimidinones and hydroxypyridazinones RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2017-02-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170204083-A1 THERAPEUTIC HYDROXYPYRIDINONES, HYDROXYPYRIMIDINONES AND HYDROXYPYRIDAZINONES XDH, DPYD, P4HA1 PARP1 612/4885PRSS1 537/4885PRSS2 1878/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback